If you don't read this message, please click here
We are excited to share that the ASMBS/IFSO Guidelines on Indications for Metabolic and Bariatric Surgery – 2022 were simultaneously published in the journals, Surgery for Obesity and Related Diseases (SOARD) and Obesity Surgery. The ASMBS/IFSO Guidelines on Indications for Metabolic and Bariatric Surgery were developed to replace the 1991 NIH Consensus Statement on Bariatric Surgery, which guided patient selection, weight-loss procedures, and obesity 30 years ago. |
Major Differences Between 1991 NIH Guidelines for Bariatric Surgery and ASMBS/IFSO Guidelines 2022 - Metabolic and Bariatric Surgery (MBS) is recommended for individuals with BMI >35 kg/m2, regardless of presence, absence, or severity of comorbidities and should be considered for individuals with metabolic disease and BMI 30-34.9 kg/m2 who do not achieve substantial or durable weight loss or comorbidity improvement using nonsurgical methods.
- BMI thresholds should be adjusted in the Asian population such that BMI >25 kg/m2 suggests clinical obesity, and individuals with BMI >27.5 kg/m2 should be offered MBS and appropriately selected children/adolescents should be considered for MBS.
- Data, including randomized clinical trials, real-world studies and the global patient experience spanning more than 30 years supports the safety, effectiveness and durability of MBS and its superiority to nonsurgical methods.
- Metabolic surgery, not mentioned in 1991, takes on new significance and prominence in 2022 for patients with lower BMIs and type 2 diabetes.
|
WATCH THE OFFICIAL PRESENTATION OF THE GUIDELINES |
|
|
IFSO Secretariat Rione Sirignano, 5 - 80121 Naples, ITALY Ph. +39 (0)81 7611085 - Fax +39 (0)81 2470383 [email protected] www.ifso.com www.ifso2023.org |
|
|
|
|
Email inviata con | | Unsubscribe | Disiscriviti |
|
|